TPH2 (Ab-19) Antibody

What is TPH2 and why is it significant in neuroscience research?

TPH2 (Tryptophan Hydroxylase 2) is the rate-limiting enzyme for the synthesis of central 5-hydroxytryptamine (5-HT, serotonin) and plays a pivotal role in modulating 5-HT neurotransmission . As the isoform predominantly expressed in the brain, TPH2 is critical for maintaining serotonergic signaling in the central nervous system. The significance of TPH2 extends beyond basic neurotransmitter synthesis to include roles in the stress response, energy balance regulation, and various neuropsychiatric disorders . TPH2 represents a promising target for therapeutic interventions in psychiatric disorders, similar to other components of the serotonergic system such as the serotonin transporter (5-HTT) and monoamine oxidase A (MAOA) .

What are the key specifications of TPH2 (Ab-19) Antibody?

TPH2 (Ab-19) Antibody is a polyclonal antibody developed in rabbits that specifically detects endogenous levels of total TPH2 protein . The antibody was generated through affinity purification from rabbit antiserum using an epitope-specific immunogen . The key specifications of this antibody are summarized in the table below:

How does TPH2 differ from TPH1 structurally and functionally?

TPH2 and TPH1 share considerable homology across the majority of their sequences but have a key structural difference: TPH2 contains an additional 41 amino acids at its N-terminus that are absent in TPH1 . This extended N-terminal domain significantly impacts the protein's expression and stability characteristics. The functional differences between these isoforms include:

• Expression levels: TPH1 is expressed at much higher levels than TPH2 in cell culture systems despite similar mRNA levels, suggesting post-transcriptional regulation differences .

• Tissue distribution: While TPH1 is predominantly expressed in peripheral tissues (particularly the gut and pineal gland), TPH2 is the primary isoform in the brain's serotonergic neurons, especially concentrated in the raphe nuclei .

• Regulatory mechanisms: The extended N-terminus of TPH2 contains regulatory sites, particularly around amino acids 11-20, that significantly reduce protein expression and stability compared to TPH1 .

• Phosphorylation sites: The N-terminal domain of TPH2 contains a serine at position 19 (Ser19), which serves as a PKA phosphorylation site that can increase protein stability when phosphorylated .

What are the optimal immunohistochemistry protocols for TPH2 detection in brain tissue?

For optimal TPH2 detection in brain tissue, researchers should follow this validated immunohistochemistry protocol:

• Tissue preparation: Fix brain tissue in 4% paraformaldehyde and process for paraffin embedding or freeze for cryosectioning.

• Antigen retrieval: For paraffin sections, deparaffinize and treat with 0.3% H₂O₂ for 10 minutes to quench endogenous peroxidase activity. Perform heat-induced epitope retrieval by incubating slides in 0.01 M sodium citrate buffer (pH 6.0) for 10 minutes at 98°C, followed by cooling to room temperature for 20 minutes .

• Blocking: Block non-specific binding with 1% BSA in PBS for 1 hour at room temperature .

• Primary antibody incubation: Apply TPH2-specific antibody (recommended dilution 1:1000 in 1% BSA in PBS) and incubate overnight at 4°C .

• Secondary antibody and detection: Incubate with biotinylated anti-rabbit IgG secondary antibody (1:200 dilution) for 30 minutes at room temperature, followed by streptavidin-tagged peroxidase. For visualization, expose to 3,3-diaminobenzidine (DAB) substrate for 2-5 minutes .

• Counterstaining: Counterstain with Meyer's hematoxylin solution for 30 seconds to visualize cellular architecture .

For fluorescence detection, substitute the streptavidin-peroxidase and DAB steps with a fluorophore-conjugated secondary antibody and analyze using a fluorescence microscope .

How can TPH2 (Ab-19) Antibody be optimized for Western blot applications?

For optimal Western blot results with TPH2 (Ab-19) Antibody, implement the following methodology:

• Protein extraction: Extract total protein from brain tissue or cultured cells using a lysis buffer containing protease inhibitors. For phosphorylation studies, include phosphatase inhibitors.

• Protein quantification and loading: Quantify protein concentration using Bradford or BCA assay. Load 20-40 μg of total protein per lane on an SDS-PAGE gel (10-12%).

• Electrophoresis and transfer: Separate proteins by SDS-PAGE and transfer to a PVDF or nitrocellulose membrane.

• Blocking: Block the membrane with 5% non-fat dry milk or BSA in TBST for 1 hour at room temperature.

• Primary antibody incubation: Dilute TPH2 (Ab-19) Antibody (recommended starting dilution 1:1000) in blocking buffer and incubate overnight at 4°C.

• Washing and secondary antibody: Wash membrane with TBST (3 × 10 minutes) and incubate with HRP-conjugated anti-rabbit secondary antibody (1:5000-1:10000) for 1 hour at room temperature.

• Detection: After washing, visualize using enhanced chemiluminescence (ECL) reagent.

• Controls and validation: Include appropriate positive controls (brain tissue lysate) and negative controls (peripheral tissue lacking TPH2 expression). For specificity validation, consider using TPH2 knockout samples or peptide competition assays.

The expected molecular weight for TPH2 is approximately 56 kDa . When analyzing phosphorylation states, particularly of Ser19, include positive controls such as lysates from PKA-activated cells (e.g., forskolin-treated) .

How can researchers generate TPH2-specific antibodies for distinct phosphorylation states?

Researchers can generate phosphorylation state-specific TPH2 antibodies by following these methodological steps:

• Peptide design: Synthesize short peptides (10-15 amino acids) containing the phosphorylated or non-phosphorylated residue of interest. For TPH2 Ser19 phosphorylation, researchers have successfully used peptides corresponding to TPH2 residues 10-24 (SKYWARRGLSLDSAV) with phosphorylated or non-phosphorylated Ser19 .

• Peptide conjugation: Conjugate the synthetic peptides to carrier proteins such as keyhole limpet hemocyanin (KLH) or bovine serum albumin (BSA) using glutaraldehyde or m-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS).

• Immunization: Immunize rabbits or other host animals with the conjugated peptide following a standard immunization protocol (initial immunization followed by 3-4 booster injections at 2-3 week intervals).

• Antibody purification: Collect serum and purify antibodies using a two-step affinity purification:

  • First, pass the antiserum through a column containing the non-phosphorylated peptide to remove antibodies that recognize the backbone regardless of phosphorylation state.

  • Then, purify phospho-specific antibodies using a column containing the phosphorylated peptide.

• Validation: Validate antibody specificity using Western blotting with lysates from cells expressing TPH2 under conditions that promote or inhibit phosphorylation (e.g., forskolin treatment to activate PKA, or PKA inhibitors) . Additional validation should include peptide competition assays and testing with phosphatase-treated samples.

For non-phosphorylation-specific antibodies, researchers have successfully generated TPH2-specific antibodies using N-terminal peptides corresponding to TPH2 residues 10-24 and 26-39 .

How does TPH2 phosphorylation at Ser19 affect serotonin synthesis in neuronal cells?

Phosphorylation of TPH2 at Ser19 significantly enhances serotonin synthesis through several mechanisms:

• Increased protein stability: Phosphorylation at Ser19 counteracts the inherent instability of TPH2 conferred by its N-terminal domain. Research indicates that PKA phosphorylation of Ser19 leads to a 2-3 fold increase in TPH2 protein levels .

• Enhanced 5-HT production: Cells expressing TPH2 with phosphomimetic mutation (S19D) show approximately 2.5-fold higher levels of 5-HT compared to wild-type TPH2, directly corresponding to the increase in protein expression .

• Experimental evidence: When PC12 cells expressing TPH2 are treated with forskolin (a PKA activator), there is a greater than 3-fold increase in 5-HTP production (p < 0.001). This effect is partially reduced but not abolished by the S19A mutation (p < 0.05), suggesting that while Ser19 phosphorylation is important, other PKA-dependent mechanisms may also contribute .

• Mechanistic pathway: The phosphorylation of Ser19 facilitates interaction with 14-3-3 proteins in a phosphorylation-dependent manner, which increases protein stability . This protein-protein interaction appears to protect TPH2 from degradation.

These findings suggest that monitoring TPH2 phosphorylation at Ser19 using phospho-specific antibodies can provide valuable insights into the dynamic regulation of serotonin synthesis in response to various physiological and pharmacological stimuli.

What are the regional differences in TPH2 expression across brain structures and how can they be accurately quantified?

TPH2 shows distinct expression patterns across different brain regions that can be quantified using various techniques:

• Primary expression sites: The highest TPH2 expression occurs in the raphe nuclei (dorsal, medial, and caudal), which are the primary sites of serotonergic neurons . Significant expression is also found in the ventral tegmental area (VTA) .

• Secondary expression sites: Detectable TPH2 expression has been documented in several other brain regions, including:

  • Pituitary

  • Hypothalamus

  • Mesencephalic tegmentum

  • Striatum

  • Hippocampus

  • Pineal gland

• Quantification methods:

  • Immunohistochemistry with cell counting: Count TPH2-positive neurons in all brain sections containing regions of interest and calculate the average number per section . This provides cellular resolution and allows for morphological assessment.

  • Western blotting: For bulk tissue analysis, dissect specific brain regions and quantify TPH2 protein levels relative to housekeeping proteins.

  • RT-qPCR: Quantify TPH2 mRNA levels in different brain regions, though this should be complemented with protein analysis due to the documented discrepancies between mRNA and protein levels for TPH2 .

• Considerations for accurate quantification:

  • Detection of TPH2 in regions outside the raphe nuclei may result from the presence of 5-HT neurons outside these nuclei or from extensive projections of serotonergic fibers .

  • When comparing regions, standardize section thickness, antibody concentrations, and incubation times.

  • Include multiple biological replicates (recommended minimum 3-8 mice per group) for statistical analysis .

What approaches should be used to study the differential regulation of TPH2 expression in stress models?

To effectively study TPH2 regulation in stress models, researchers should employ a comprehensive multi-level approach:

• Animal models of stress:

  • Acute stress: Restraint stress, forced swim test, or social defeat paradigms

  • Chronic stress: Chronic unpredictable mild stress, chronic social defeat, or chronic restraint stress

  • Early life stress: Maternal separation or prenatal stress exposure

• Molecular analysis methods:

  • Transcriptional regulation: Quantify TPH2 mRNA expression using RT-qPCR in specific brain regions after stress exposure .

  • Epigenetic modifications: Assess DNA methylation and histone modifications at the TPH2 promoter and regulatory regions using bisulfite sequencing and chromatin immunoprecipitation (ChIP) .

  • Protein expression: Measure total TPH2 protein levels and phosphorylation states (particularly at Ser19) using Western blotting with specific antibodies .

• Functional assessments:

  • Enzyme activity: Measure 5-HTP accumulation after decarboxylase inhibition (e.g., with NSD-1015) using HPLC to assess TPH2 activity .

  • 5-HT tissue content: Quantify 5-HT levels in brain tissue using HPLC to correlate with TPH2 expression changes.

• Mechanistic investigations:

  • Glucocorticoid signaling: Examine the role of stress hormones in TPH2 regulation using glucocorticoid receptor antagonists or adrenalectomy .

  • PKA signaling: Investigate stress-induced changes in PKA activity and its impact on TPH2 Ser19 phosphorylation using PKA activators (forskolin) or inhibitors .

  • Genetic approaches: Utilize conditional TPH2 knockouts or overexpression models to determine the causal relationship between stress, TPH2 expression, and behavioral outcomes.

• Temporal dynamics: Assess both rapid (hours) and long-term (days to weeks) changes in TPH2 expression and activity following stress exposure to distinguish between acute responses and adaptive changes.

By implementing this comprehensive approach, researchers can elucidate the complex interplay between stress, TPH2 regulation, and serotonergic neurotransmission, which has significant implications for stress-related psychiatric disorders .

What are common pitfalls in TPH2 antibody experiments and how can they be avoided?

Researchers frequently encounter several challenges when working with TPH2 antibodies. Here are common pitfalls and solutions:

• Cross-reactivity with TPH1:

  • Problem: Many commercial antibodies fail to distinguish between TPH1 and TPH2 due to sequence homology.

  • Solution: Use antibodies specifically targeting the unique N-terminal region of TPH2 (amino acids 1-41) . Validate specificity using TPH2 knockout tissues or cells expressing only TPH1 or TPH2.

• Nonspecific binding:

  • Problem: High background signal in immunohistochemistry or Western blot.

  • Solution: Optimize blocking conditions (try 3-5% BSA or 5% milk). For TPH2 (Ab-19) Antibody, use 1% BSA in PBS for optimal blocking . Include additional washing steps and consider using more stringent washing buffers (higher salt or detergent concentration).

• Inconsistent detection of phosphorylated TPH2:

  • Problem: Difficulty detecting phosphorylated TPH2 at Ser19.

  • Solution: Include phosphatase inhibitors in all buffers during sample preparation. Use positive controls such as forskolin-treated samples that increase PKA activity . Consider using phospho-mimetic (S19D) and phospho-dead (S19A) TPH2 mutants as controls.

• Variable expression levels:

  • Problem: Inconsistent TPH2 detection between experiments.

  • Solution: Standardize protein extraction protocols and loading amounts. Consider the impact of circadian rhythms and stress on TPH2 expression when designing experiments . When possible, collect samples at the same time of day.

• Poor immunohistochemical detection:

  • Problem: Weak or no signal in tissue sections.

  • Solution: Optimize antigen retrieval conditions (the 0.01 M sodium citrate buffer at pH 6.0 for 10 minutes at 98°C is recommended for TPH2) . Ensure proper tissue fixation and processing. Increase antibody concentration or incubation time if signal is weak.

How should researchers interpret discrepancies between TPH2 mRNA and protein levels in experimental data?

When confronted with discrepancies between TPH2 mRNA and protein levels, researchers should consider the following interpretation framework:

• Documented disconnect: Studies have shown that TPH1 and TPH2 can have similar mRNA levels despite significant differences in protein expression . This indicates post-transcriptional or post-translational regulation rather than experimental error.

• N-terminal regulatory elements: The N-terminal domain of TPH2, particularly amino acids 11-20, has been demonstrated to reduce protein expression despite normal mRNA transcription . This region affects both protein synthesis and stability.

• Interpretation strategies:

  • Time course analysis: Measure both mRNA and protein at multiple time points to detect temporal delays between transcription and translation.

  • Half-life assessment: Determine protein stability using cycloheximide chase experiments to assess if differences are due to altered protein degradation rates.

  • Polysome profiling: Examine if TPH2 mRNA is effectively loaded onto polysomes for translation.

• Factors affecting the mRNA-protein relationship:

  • Phosphorylation status: Phosphorylation at Ser19 increases TPH2 protein stability without affecting mRNA levels .

  • Stress and glucocorticoids: These can differentially regulate TPH2 at transcriptional and post-translational levels .

  • microRNA regulation: Consider potential microRNA-mediated inhibition of translation without mRNA degradation.

• Experimental validation approaches:

  • Use proteasome inhibitors to determine if protein degradation contributes to low protein levels despite high mRNA.

  • Examine the effect of PKA activation (e.g., with forskolin) on protein levels without affecting mRNA.

  • Create reporter constructs containing the TPH2 5' UTR and N-terminal coding region to assess translational efficiency.

Understanding these mechanisms is crucial for accurate interpretation of experimental results and for developing interventions that effectively modulate TPH2 levels and serotonergic function.

How can researchers effectively distinguish between TPH2 expression changes due to circadian rhythms versus stress responses?

Distinguishing between circadian and stress-induced changes in TPH2 expression requires careful experimental design:

• Temporal controls:

  • Circadian sampling: Collect samples at multiple time points across the 24-hour cycle (minimum 4-6 time points) to establish the normal circadian pattern of TPH2 expression.

  • Time-matched controls: For stress studies, always include non-stressed controls sacrificed at the same time of day as stressed animals.

• Experimental design strategies:

  • Constant conditions: House animals in constant darkness or constant light for 24-48 hours before sampling to distinguish endogenous rhythms from light-driven changes.

  • Cross-factorial design: Apply stress manipulations at different circadian time points to detect interactions between circadian phase and stress response.

  • Genetic approaches: Utilize clock gene mutants (e.g., Clock, Bmal1 knockout mice) to determine which TPH2 expression changes persist in the absence of a functional circadian clock.

• Molecular markers:

  • Circadian markers: Measure expression of core clock genes (Per1, Per2, Bmal1) in the same samples to correlate with TPH2 expression.

  • Stress markers: Assess plasma corticosterone levels and expression of stress-responsive genes (e.g., CRH, GR) to confirm stress activation.

  • Phosphorylation status: Evaluate TPH2 Ser19 phosphorylation, which responds to stress-activated PKA signaling but may have different patterns in circadian regulation .

• Analysis approaches:

  • Cosinor analysis: Apply cosinor regression to determine circadian parameters (amplitude, phase, mesor) of TPH2 expression.

  • ANOVA with circadian time as factor: Use statistical approaches that account for both circadian time and stress condition as factors.

  • Individual variation analysis: Correlate individual differences in stress hormone levels with TPH2 expression changes to identify stress-specific effects.

• Tissue-specific considerations:

  • The raphe nuclei may show different circadian patterns of TPH2 expression compared to other brain regions like the pineal gland.

  • Consider examining multiple brain regions to distinguish global from region-specific circadian or stress effects .

By implementing these methodological approaches, researchers can effectively disentangle the complex interplay between circadian regulation and stress responses in the control of TPH2 expression and serotonergic function.

How can TPH2 (Ab-19) Antibody contribute to understanding sex differences in serotonergic signaling?

TPH2 (Ab-19) Antibody offers valuable tools for investigating sex differences in serotonergic signaling through several research approaches:

• Quantitative analyses across sexes:

  • Using TPH2 (Ab-19) Antibody, researchers can quantify TPH2 protein levels in male versus female brain tissues through Western blotting and immunohistochemistry.

  • Recent findings indicate that the dorsal raphe nuclei harbor similar amounts of TPH2 in adult male and female mice, suggesting the need for more nuanced investigations beyond simple quantity differences .

• Phosphorylation status assessment:

  • Since TPH2 (Ab-19) Antibody targets the region around Ser19, researchers can develop complementary phospho-specific antibodies to determine if sex differences exist in basal or stimulated phosphorylation levels of TPH2 .

  • This approach could reveal sex-specific post-translational regulation even when total protein levels are similar.

• Hormone-dependent regulation:

  • Investigate how sex hormones (estrogen, progesterone, testosterone) differentially regulate TPH2 expression and phosphorylation across sexes.

  • Combine TPH2 (Ab-19) Antibody with hormone receptor antibodies in co-immunoprecipitation or co-localization studies to examine direct interactions.

• Developmental trajectories:

  • Track TPH2 expression across development in both sexes to identify critical periods when sexual differentiation of the serotonergic system occurs.

  • This could reveal developmental windows for sex-specific interventions in serotonin-related disorders.

• Stress response differences:

  • Investigate how TPH2 expression and phosphorylation respond to various stressors in a sex-dependent manner .

  • This is particularly relevant given the higher prevalence of stress-related mood disorders in females.

• Translation to human studies:

  • As TPH2 (Ab-19) Antibody is specific for human TPH2 , it can be used in postmortem brain studies to validate findings from animal models in human tissue and examine potential sex differences in TPH2 expression in neuropsychiatric disorders.

What is the role of TPH2 in energy metabolism regulation and how can it be investigated using TPH2 antibodies?

The role of TPH2 in energy metabolism can be comprehensively investigated using TPH2 antibodies through the following approaches:

How can researchers integrate TPH2 protein studies with genetic and epigenetic approaches to understand psychiatric disorders?

Integrating TPH2 protein studies with genetic and epigenetic approaches provides a comprehensive framework for understanding psychiatric disorders:

• Multi-level integration strategies:

  • Genotype-protein expression correlation: Use TPH2 antibodies to measure protein levels in individuals with different TPH2 genetic variants to establish functional consequences of genetic polymorphisms.

  • Epigenetic-protein regulation: Correlate TPH2 promoter methylation or histone modifications with protein expression levels across brain regions relevant to psychiatric disorders.

  • Environmental interaction studies: Examine how environmental factors (stress, early life adversity) affect both epigenetic marks and TPH2 protein expression/phosphorylation .

• Methodological approaches:

  • ChIP-Western methodology: Combine chromatin immunoprecipitation to assess histone modifications at the TPH2 gene with Western blotting to measure resulting protein levels in the same samples.

  • Tissue-specific analyses: Compare TPH2 epigenetic modifications and protein expression in different brain regions using region-specific tissue dissection followed by parallel epigenetic and protein analyses.

  • Single-cell approaches: Implement single-cell proteomics and epigenomics to examine cell-specific variations in TPH2 regulation within heterogeneous brain tissue.

• Clinical applications:

  • Use TPH2 (Ab-19) Antibody in postmortem brain studies of psychiatric patients to correlate protein expression with known genetic risk variants.

  • Develop peripheral biomarkers by examining if blood cell TPH2 epigenetic marks correlate with brain TPH2 protein levels in animal models.

  • Stratify patients in clinical trials based on TPH2 genetic variants and monitor treatment response.

• Mechanistic insights:

  • Investigate how specific genetic variants alter TPH2 protein stability, phosphorylation, or interaction with regulatory proteins .

  • Determine if epigenetic modifications affect the accessibility of transcription factors to regions controlling expression of proteins that regulate TPH2 phosphorylation.

  • Examine the relationship between stress-induced epigenetic changes and alterations in TPH2 Ser19 phosphorylation .

• Technological integration:

  • Combine CRISPR-mediated gene editing to introduce specific TPH2 variants with antibody-based detection to assess functional consequences.

  • Utilize induced pluripotent stem cells (iPSCs) from patients with different TPH2 genotypes, differentiate them into serotonergic neurons, and analyze protein expression and function using TPH2 antibodies.

  • Apply proteomic approaches to identify the complete interactome of TPH2 and how it is affected by genetic variants or epigenetic modifications.

This integrative approach would provide a more comprehensive understanding of how genetic, epigenetic, and post-translational modifications of TPH2 contribute to psychiatric disorders and could lead to more personalized treatment approaches.